Compare Amylx Pharmaceuticals Inc (AMLX) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs McCormick & Company, Incorporated — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while McCormick & Company, Incorporated trades at $52.88 (market cap $14.08B). The key difference: McCormick & Company, Incorporated is far larger — about 7.1× Amylx Pharmaceuticals Inc's market cap, and McCormick & Company, Incorporated pays a 3.66% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | MKC | |
|---|---|---|
Market Cap | $1.98B | $14.08B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $72.81 |
52-Week Low | $7.64 | $45.60 |
Enterprise Value | $1.70B | $18.68B |
Dividend Yield | — | 3.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
McCormick (MKC) trades at $52.45, up 1.77% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 21.91% net income margin and 25.7% ROE, supported by a transformative $45 billion Unilever Foods deal announced in July 2026. Valuation appears attractive with a P/E of 8.73, below industry averages, while cash flow trends indicate robust operational performance.
The outlook is mixed; analyst consensus targets $59.67 (14% upside) with a 'Hold' bias, but weak consumer volume growth and integration risks from the Unilever acquisition pose challenges. The stock offers a near 4% dividend yield, providing income support, yet execution on cost savings and volume recovery remains critical for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
